Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2016 1
2017 2
2018 3
2019 2
2020 3
2021 7
2022 7
2023 7
2024 8
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Tienhoven G, van Eijck CHJ; Dutch Pancreatic Cancer Group. Versteijne E, et al. Among authors: luelmo sac. J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27. J Clin Oncol. 2022. PMID: 35084987 Clinical Trial.
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G; Dutch Pancreatic Cancer Group. Versteijne E, et al. Among authors: luelmo sac. J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27. J Clin Oncol. 2020. PMID: 32105518 Free PMC article. Clinical Trial.
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, Bouwense SAW, Brouwer-Hol L, Bruynzeel AME, Busch OR, Coene PLO, van Eijck CHJ, de Groot JWB, Haberkorn BCM, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Loosveld OJL, Luelmo SAC, Luyer MDP, Mekenkamp LJM, Mieog JSD, Nieuwenhuijs VB, Nuyttens JJME, Patijn GA, van Santvoort HC, Stommel MWJ, Versteijne E, de Vos-Geelen J, de Wilde RF, Zonderhuis BM, van der Holt B, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Janssen QP, et al. Among authors: luelmo sac. Lancet Oncol. 2025 Oct;26(10):1346-1356. doi: 10.1016/S1470-2045(25)00363-8. Epub 2025 Sep 10. Lancet Oncol. 2025. PMID: 40945523 Clinical Trial.
Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol.
Stoop TF, Seelen LWF, van 't Land FR, van der Hout AC, Scheepens JCM, Ali M, Stiggelbout AM, van der Kolk BM, Bonsing BA, Lips DJ, de Groot DJA, van Veldhuisen E, Kerver ED, Manusama ER, Daams F, Kazemier G, Cirkel GA, van Tienhoven G, Patijn GA, Lelieveld-Rier HN, de Hingh IH, van Hellemond IEG, Wijsman JH, Erdmann JI, Mieog JSD, de Vos-Geelen J, de Groot JWB, Lutchman KRD, Mekenkamp LJ, Kranenburg LW, Beuk LPM, Nijkamp MW, den Dulk M, Polée MB, Homs MYV, Wumkes ML, Stommel MWJ, Busch OR, de Wilde RF, Theijse RT, Luelmo SAC, Festen S, Bollen TL, Neumann UP, de Meijer VE, Draaisma WA, Groot Koerkamp B, Molenaar IQ, Wolfgang CL, Del Chiaro M, Katz MGH, Hackert T, Rietjens JAC, Wilmink JW, van Santvoort HC, van Eijck CHJ, Besselink MG; Dutch Pancreatic Cancer Group. Stoop TF, et al. Among authors: luelmo sac. BMC Cancer. 2025 Feb 19;25(1):299. doi: 10.1186/s12885-025-13554-w. BMC Cancer. 2025. PMID: 39972248 Free PMC article.
Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
Esteves S, Costa I, Luelmo S, Santarém N, Cordeiro-da-Silva A. Esteves S, et al. Among authors: luelmo s. Microorganisms. 2022 Dec 8;10(12):2435. doi: 10.3390/microorganisms10122435. Microorganisms. 2022. PMID: 36557688 Free PMC article. Review.
Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.
Mackay TM, Latenstein AEJ, Augustinus S, van der Geest LG, Bogte A, Bonsing BA, Cirkel GA, Hol L, Busch OR, den Dulk M, van Driel LMJW, Festen S, de Groot DA, de Groot JB, Groot Koerkamp B, Haj Mohammad N, Haver JT, van der Harst E, de Hingh IH, Homs MYV, Los M, Luelmo SAC, de Meijer VE, Mekenkamp L, Molenaar IQ, Patijn GA, Quispel R, Römkens TEH, van Santvoort HC, Stommel MWJ, Venneman NG, Verdonk RC, van Vilsteren FGI, de Vos-Geelen J, van Werkhoven CH, van Hooft JE, van Eijck CHJ, Wilmink JW, van Laarhoven HWM, Besselink MG; Dutch Pancreatic Cancer Group. Mackay TM, et al. Among authors: luelmo sac. JAMA Surg. 2024 Apr 1;159(4):429-437. doi: 10.1001/jamasurg.2023.7872. JAMA Surg. 2024. PMID: 38353966 Free PMC article. Clinical Trial.
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial.
Dekker EN, Theijse RT, van Dam JL, Janssen QP, Stoop TF, Bonsing BA, Bosscha KP, Bouwense SAW, Busch OR, Coene PLO, van Eijck CHJ, van Her Harst E, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Mieog JSD, Nieuwenhuijs VB, Patijn GA, van Santvoort HC, Schreinemakers JMJ, de Wilde RF, Wit F, Zonderhuis BM, Homs MYV, van Tienhoven G, Wilmink JW, Besselink MG, Koerkamp BG; Dutch Pancreatic Cancer Group. Dekker EN, et al. Ann Surg. 2025 Aug 12. doi: 10.1097/SLA.0000000000006910. Online ahead of print. Ann Surg. 2025. PMID: 40792645
PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.
Kleiburg F, de Geus-Oei LF, Luelmo SAC, Spijkerman R, Goeman JJ, Toonen FAJ, Smit F, van der Hulle T, Heijmen L. Kleiburg F, et al. Among authors: luelmo sac. Eur J Radiol. 2024 Dec;181:111774. doi: 10.1016/j.ejrad.2024.111774. Epub 2024 Oct 2. Eur J Radiol. 2024. PMID: 39442347 Free article.
Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients.
Kleiburg F, de Geus-Oei LF, Spijkerman R, Noortman WA, van Velden FHP, Manohar S, Smit F, Toonen FAJ, Luelmo SAC, van der Hulle T, Heijmen L. Kleiburg F, et al. Among authors: luelmo sac. Eur Radiol. 2025 Jul;35(7):4223-4232. doi: 10.1007/s00330-025-11360-3. Epub 2025 Jan 22. Eur Radiol. 2025. PMID: 39843627 Free PMC article.
43 results